Immunological characterization of a rat model of Duchenne’s disease and increase in muscle strength after anti-CD45RC antibody treatment

Abstract : In this study, we phenotyped by flow cytometry and immunohistochemistry (data not shown) the immune cell subsets infiltrating Dmd mdx rat skeletal and cardiac muscles. Leukocyte infiltrates were absent or very low at 2 weeks of age, peaked at 4 and 8 weeks and decreased at 12 weeks. M2 macrophages represented >90% of infiltrating immune cells and Teff cells were the majority of the remaining ones. We also analyzed muscle enzymes and cytokines in sera. Creatin kinase was increased at weeks 4 and 8 and decreased at week 12 and thereafter (data not shown). This results are consistent with those observed in mdx mice model. Anti-CD45RC MAb treatment of young Dmd mdx rats normalized skeletal muscle strength associated to a depletion of effectors CD45RC high cells and no obvious side-effects. As a control prednisolone treatment of Dmd mdx rats similarly increased skeletal muscle strength and was also associated to a depletion of effectors CD45RC high cells but resulted in severe weight loss. Conclusion Duchenne Muscular Dystrophy (DMD) is a severe genetic muscle-wasting disorder due to the lack of dystrophin characterized by a progressive muscle weakness and a cardiomyopathy leading to premature death. The dystrophin-deficient Dmd mdx rats were generated using TALENs and offer a more reliable representation of human DMD, with marked muscle strength reduction, cardiomyopathy and muscle fibrosis that are higher that those observed in the mdx mouse model (1). A role for inflammation and autoimmune responses in muscle damages was shown both in DMD patients and the mdx mouse model (2). In this study, we assessed by flow cytometry and immunohistochemistry the immune cell subsets infiltrating Dmd mdx rat skeletal and cardiac muscles especially immunoregulatory and pro-inflammatory subsets (M1 and M2 macrophages, CD4 + and CD8 + Teff or Tregs…). Then, we investigated the possibility of reducing disease in Dmd mdx rats by administrating immunomodulatory treatments. The standard therapy for DMD patients is corticoids that decrease inflammation and immune responses but with variable responses, limited efficacy and important and numerous side effects. Therefore, there is need for new anti-inflammatory and pro-tolerogenic treatments that could replace or decrease the doses of corticoids. Anti-CD45RC monoclonal antibody (MAb) treatment has induced immune tolerance in models of organ transplantation and GVHD.
Document type :
Poster communications
Complete list of metadatas

https://www.hal.inserm.fr/inserm-02161104
Contributor : Ana Paula Dutra Azevedo <>
Submitted on : Thursday, June 20, 2019 - 2:24:00 PM
Last modification on : Friday, June 21, 2019 - 1:48:18 AM

File

poster DMD Labex IGO Avril 201...
Files produced by the author(s)

Identifiers

  • HAL Id : inserm-02161104, version 1

Collections

Citation

Laure-Hélène Ouisse, Séverine Rémy, Thibaut Larcher, Aude Lafoux, Laurent Tesson, et al.. Immunological characterization of a rat model of Duchenne’s disease and increase in muscle strength after anti-CD45RC antibody treatment. 3rd IGO SUMMER MEETING, Apr 2018, Nantes, France. ⟨inserm-02161104⟩

Share

Metrics

Record views

40

Files downloads

17